These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3538753)

  • 1. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine.
    Orholm M; Honoré PF; Zeeberg I
    Acta Neurol Scand; 1986 Sep; 74(3):235-9. PubMed ID: 3538753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Femoxetine in the prophylaxis of migraine--a randomised comparison with placebo.
    Zeeberg I; Orholm M; Nielsen JD; Honore PL; Larsen JJ
    Acta Neurol Scand; 1981 Dec; 64(6):452-9. PubMed ID: 6753446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study.
    Andersson PG; Petersen EN
    Acta Neurol Scand; 1981 Oct; 64(4):280-8. PubMed ID: 7032183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in platelet function and blood serotonin level in migraine patients during treatment with femoxetine.
    Dalsgaard-Nielsen J; le Fèvre Honoré P; Zeeberg I
    Acta Neurol Scand; 1982 Aug; 66(2):191-8. PubMed ID: 6982585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Femoxetine - a new 5-HT uptake inhibitor - and propranolol in the prophylactic treatment of migraine.
    Kangasniemi PJ; Nyrke T; Lang AH; Petersen E
    Acta Neurol Scand; 1983 Oct; 68(4):262-7. PubMed ID: 6606930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Femoxetine in the treatment of obese patients in general practice. A randomized group comparative study with placebo.
    Bitsch M; Skrumsager BK
    Int J Obes; 1987; 11(2):183-90. PubMed ID: 3301710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state visual evoked potentials during migraine prophylaxis by propranolol and femoxetine.
    Nyrke T; Kangasniemi P; Lang AH; Petersen E
    Acta Neurol Scand; 1984 Jan; 69(1):9-14. PubMed ID: 6608203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. So-called "tension headache"--the response to a 5-HT uptake inhibitor: femoxetine.
    Sjaastad O
    Cephalalgia; 1983 Mar; 3(1):53-60. PubMed ID: 6850822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis.
    Chabi A; Zhang Y; Jackson S; Cady R; Lines C; Herring WJ; Connor KM; Michelson D
    Cephalalgia; 2015 Apr; 35(5):379-88. PubMed ID: 25106663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo.
    Schrader H; Kayed K; Bendixen Markset AC; Treidene HE
    Acta Neurol Scand; 1986 Oct; 74(4):297-303. PubMed ID: 3544654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison.
    Skrumsager BK; Jeppesen K
    Pharmacopsychiatry; 1986 Sep; 19(5):368-77. PubMed ID: 3774871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
    Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
    Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divalproex sodium in migraine prophylaxis: a dose-controlled study.
    Klapper J
    Cephalalgia; 1997 Apr; 17(2):103-8. PubMed ID: 9137847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis.
    Meissner K; Fässler M; Rücker G; Kleijnen J; Hróbjartsson A; Schneider A; Antes G; Linde K
    JAMA Intern Med; 2013 Nov; 173(21):1941-51. PubMed ID: 24126676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications.
    Cady RK; Voirin J; Farmer K; Browning R; Beach ME; Tarrasch J
    Headache; 2012 May; 52(5):749-64. PubMed ID: 22188311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
    Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
    Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance of femoxetine and imipramine in the treatment of depressive states. A randomized, double-blind study.
    Suominen J; Tamminen T; Elosuo R; Manniche PM
    Pharmacopsychiatry; 1988 Sep; 21(5):238-44. PubMed ID: 3067246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.